Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » TransCure BioServices

TransCure BioServices

TransCure BioServices is a France-based contract research organization (CRO) specializing in preclinical research using humanized mouse models with reconstituted human immune systems. The company maintains a strategic collaboration with PhoenixBio.
This article provides an overview of TransCure BioServices’ core strengths and its portfolio of disease models.

Reference: Phoenix Bio official website (https://ssl4.eir-parts.net/doc/6190/tdnet/2182305/00.pdf)

Features of TransCure BioServices’ Contract Services for Non-Clinical Studies

Research support focused on flexibility and transparency

TransCure BioServicessupports the development of novel therapiesby combining innovative scientific expertise with highly personalized project support. Emphasizing flexibility and transparency, the company leverages advanced mouse models to closely align preclinical studies with client-specific research objectives.

Proprietary humanized mouse models with reconstituted human immune systems

A defining strength of TransCure BioServices lies inits proprietary humanized mouse models, generated by engrafting human hematopoietic stem cells into immunodeficient mice. These models enable the evaluation of human-specific immune responses at the preclinical stage—an area that has traditionally been difficult to address using conventional animal models.

AAALAC accreditation and commitment to responsible animal research

TransCure BioServices is committed to conducting responsible and ethical preclinical research and has beenfully accredited by AAALAC International since 2022.This accreditation reflects the company’s adherence to the highest standards of animal care and use. The company applies the principles of the 3Rs (Reduction, Refinement, and Replacement), using only the minimum number of animals required to generate high-quality and predictive data, while ensuring optimal housing and experimental conditions.

In addition, its Institutional Animal Care and Use Committee (IACUC) is composed of highly qualified scientists, veterinarians, technical staff, and animal welfare specialists, ensuring animal care practices and experimental procedures that exceed regulatory requirements.

Example of Disease Models Available at TransCure bioServices

TransCure BioServices develops advanced translational humanized mouse models with functional human immune systems. By engrafting CD34+ hematopoietic cells derived from human umbilical cord blood into highly immunodeficient mice,the company provides a powerful in vivo platform for evaluating human-specific immunotherapies.The company is doing so.

In addition to these models, TransCure BioServices offers a broad range of preclinical models, including standard immunodeficient and immunocompetent mouse models, dual-humanized mouse models, and humanized liver mouse models.

TransCure BioServices Non-Clinical Case Studies

Humanized mouse models in preclinical research on sickle cell disease

TransCure BioServices made a significant contribution to a study led by Arianna Moiani and colleagues, published in Nature Communications. In this research, humanized mouse models engrafted with CD34+ hematopoietic stem cells were used to investigate sickle cell disease (SCD),enabling a more accurate recapitulation of human disease pathology.
This innovative preclinical approach allows for more precise evaluation of therapeutic candidates targeting hemoglobinopathies and associated complications.

Referenced from: TransCure BioServices official website (https://www.transcurebioservices.com/scientific-publications/humanized-mouse-models-sickle-cell- disease-preclinical-research/)

TransCure BioServices Company Information

TransCure BioServices is a French CRO dedicated to preclinical research using humanized mouse models. With more than 10 years of experience supporting preclinical studies across a wide range of advanced mouse models, the company possesses the scientific expertise and translational insight required to meet the complex needs of its clients.

AddressArchamps Technopole, Bâtiment de l'Alliance, 74160 Archamps, France
Tel+33 (0)4 50 43 01 02
Websitehttps://www.transcurebioservices.com/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approach allows researchers to discuss and refine study plans together with SMC’s expert scientists.
  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd. offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to–drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides a seamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
  • The company offers an integrated evaluation analysis covering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.
By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services